Why Molecular Partners AG’s (MOLN) Stock Is Down 8.53%
As of Monday, June 08, Molecular Partners AG’s MOLN share price has dipped by 8.53%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Commentary & Analysis
Why Molecular Partners AG’s (MOLN) Stock Is Up 7.89%
As of Friday, May 22, Molecular Partners AG’s MOLN share price has surged by 7.89%, which has investors questioning if this is right time to sell.Michael Rose
Why Molecular Partners AG’s (MOLN) Stock Is Down 5.62%
As of Thursday, April 30, Molecular Partners AG’s MOLN share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Michael Rose
Why Molecular Partners AG’s (MOLN) Stock Is Up 10.08%
As of Wednesday, April 08, Molecular Partners AG’s MOLN share price has surged by 10.08%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Molecular Partners AG’s (MOLN) Stock Is Up 12.40%
As of Wednesday, April 08, Molecular Partners AG’s MOLN share price has surged by 12.40%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $154.5 | $252.6 | 25% |
|
| Shares Out (Mil) | 46.8 | 52.3 | 46% |
|
| Institutional Ownership | 68.1% | 92.1% | 42% |
|
| Float (Mil) | 19.9 | 40.2 | 29% |
|
| Beta | 0.71 | 0.95 | 41% |
|
| Avg Daily Volume (000s) | 1 | 455 | 4% |
|
| Price Change (52-week) |
2.9% | 52.9% | 48% |
|
| Growth | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (1.8%) | (9.9%) | 37% |
|
| EPS (5yr) | 6.0% | 16.0% | 39 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.4%) | (15.6%) | 23% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 3 | 3 | |
| Current EPS | ($0.433) | ($1.439) | ($0.259) | |
| Month Ago EPS | ($0.420) | ($1.268) | $0.285 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.414) | ($1.268) | $0.285 | |
| Year/Year Chg | (0.9%) | (31.0%) | (27.5%) | |
| Financials | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($72) | ($43) | 13% |
|
| EPS (TTM) | ($1.933) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($60) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($21) | $5 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $5 | 21% |
|
| Enterprise Value (Q1) (Mil) | $52 | $180 | 16% |
|
| Valuation | MOLN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.72 | 2.56 | 45% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (53.8%) | (49.8%) | 11% |
|
| ROE | (62.8%) | (55.5%) | 13% |
|
| Liabilities to Assets | 21.9% | 30.3% | 14% |
|
| F-Score | 1 | 3 | 1% |
|
Molecular Partners AG did not pass any screens on 7/31/2026.
